Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sonoma Pharmaceuticals (SNOA) has shared an update.
During the adjourned annual meeting on August 23, 2024, Sonoma Pharmaceuticals, Inc.’s stockholders made several key decisions including the election of two Class I directors, approval of executive compensation, and rejection of the company’s reincorporation from Delaware to Nevada. Additionally, they approved an increase in authorized shares, the 2024 Equity Incentive Plan, a reverse stock split, and the appointment of a new independent accounting firm. These decisions will significantly shape the company’s governance and financial strategy moving forward. A press release regarding the reverse stock split was subsequently issued.
See more insights into SNOA stock on TipRanks’ Stock Analysis page.
